Furacilin-LekT

Quick links

Choose a section

Quick links to important sections

Advertisements

Furacilin-LekT

Selected form

Advertisements
Advertisements

Overview of Furacilin-LekT

Property Description
Active ingredient Nitrofural (Nitrofurazone)
Form Tablets for solution; Aqueous solution; Ointment
Pharmacological class Antiseptic Agent; Synthetic Antimicrobial
Common use Local infection prophylaxis and management
Origin Synthetic (Nitrofuran derivative)

Furacilin-LekT is a medicinal preparation whose active component is the established pharmaceutical ingredient Nitrofural, also recognized as Nitrofurazone. This specific formulation, typically supplied in various forms for versatility, is classified as a synthetic antimicrobial agent and an antiseptic agent specifically intended for external use. As a nitrofuran derivative, its classification is based on its chemical structure.

Composition and General Antimicrobial Purpose

The core purpose of the active ingredient, Nitrofural, is to manage the presence of microorganisms on the skin and superficial tissue, thus supporting local infection control. Nitrofural acts by achieving broad-spectrum activity against various common bacterial pathogens, including both Gram-positive and Gram-negative species. This means the substance effectively targets a wide range of bacteria responsible for localized infections. Nitrofural functions by inhibiting several critical enzyme systems within bacterial cells, which results in both a bacteriostatic effect (preventing multiplication) and a bactericidal effect (killing the bacteria).

Available Forms for Topical Application

Furacilin-LekT is designed exclusively for topical application and offers its strength through its adaptable dosage forms. Its primary preparation is the tablets for solution preparation, which are used to create a fresh aqueous solution suitable for cleansing and irrigation. Alternatively, the medicine may be supplied as an ointment formulation. These distinct forms allow the user to select the appropriate medium to ensure the Nitrofural is effectively delivered to the targeted external area, maintaining its established role in antiseptic care.

Regulatory References

  1. Nitrofural (Nitrofurazone) - NCBI Bookshelf
Advertisements

What side effects are possible with Furacilin-LekT?

Possible side effects and safety information

This information describes the official adverse reactions and safety characteristics of the active ingredient, Nitrofural (Nitrofurazone), based strictly on government regulatory documents, such as FDA Prescribing Information.


Adverse Reaction Scope

The most commonly documented adverse events for topical Nitrofural fall within the Skin and Subcutaneous Tissue Disorders system organ class. These reactions are typically local and may include irritation at the application site or sensitization reactions, which can manifest as dermatitis, rash, or pruritus (itching).

Category Description based on Regulatory Data
Frequency Classification Adverse events are generally described in terms of historical occurrence rather than formal regulatory frequency categories (e.g., Common, Uncommon).
Serious Adverse Reactions No systemic toxicity is reported as clinically significant for topical use. The most clinically relevant adverse responses are the development of severe hypersensitivity or superinfection, both of which require mandatory discontinuation of the medicine.

Safety-Related Restrictions and Considerations

The medicine is contraindicated in individuals with a known hypersensitivity to nitrofural or any nitrofuran derivative. Official regulatory documents mandate that treatment must be discontinued if signs of irritation, local sensitization, or the overgrowth of non-susceptible organisms (superinfection) occur.

Regarding special populations, the safe use of Nitrofural during pregnancy has not been established in regulatory documents and is therefore a safety consideration. The overall safety structure confirms that the primary risks are localized, non-systemic, and manageable by discontinuing therapy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with drugs containing Nitrofural, particularly if excessive amounts are systemically absorbed, can be associated with severe physiological effects. The official regulatory profile emphasizes that acute toxicity requires immediate medical management due to the potential for serious outcomes.

Documented Overdose Symptoms

The established overdose presentation primarily involves systemic disturbances, which may include:

  • Gastrointestinal Issues: Nausea and vomiting.
  • Nervous System Effects: Signs of acute polyneuritis (nerve damage), cerebellar dysfunction, and in severe cases, convulsions or tremors.
  • Hematologic Changes: Anemia, and bleeding tendencies.
  • Circulatory Instability: Circulatory collapse.

Over-absorption, especially in individuals with pre-existing impaired renal function or when applied to large areas (e.g., severe burns), can lead to progressive renal impairment characterized by increased blood urea nitrogen (BUN) and metabolic acidosis. This is a critical, high-risk situation.

Emergency Medical Action

Emergency medical help must be sought immediately if any of the following are suspected or observed after excessive exposure:

  • Severe, persistent vomiting or signs of systemic illness.
  • Signs of acute neurological changes (e.g., seizures, pronounced weakness, loss of coordination).
  • Any sign of allergic reaction, such as difficulty breathing, swelling, or rash extending beyond the application site.

Treatment is entirely symptomatic and supportive. There is no specific pharmacological antidote to reverse the effects of Nitrofural overdose. Management focuses on maintaining the patient's vital functions and providing supportive care until the drug is eliminated from the body, as outlined in official prescribing information.

Advertisements

Therapeutic Uses of Furacilin-LekT

The primary role of Furacilin-LekT (Nitrofural) is relevant for easing symptoms related to inflammatory or irritative states linked to surface bacterial activity. Applications include several key therapeutic areas where localized support is needed.

Managing Localized Skin and Soft Tissue Infections

The medication is commonly used for managing symptom clusters that create noticeable physiological strain, such as those associated with various skin and soft tissue infections or chronic lesions, including trophic ulcers, pressure ulcers, and the infectious component of severe skin trauma like second and third-degree burns. Additionally, it may be part of symptomatic management for acute, localized inflammations of accessible surfaces, such as acute tonsillitis, stomatitis, gingivitis, and otitis externa. The primary benefit contributes to easing the overall symptom load linked to localized bacterial activity.


“It is applied in scenarios where additional management of discomfort is required, which may help address the risk of infection in open tissues and mucosal areas.”


Quick Fact: Relief for Localized Infection Symptoms Furacilin-LekT supports general well-being during symptomatic phases by assisting with managing discharge and reducing the inflammatory discomfort associated with superficial bacterial colonization.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Furacilin-LekT

The eligibility profile for Furacilin-LekT (Nitrofural) is defined by official regulatory documentation, establishing absolute prohibitions and restricted-use populations.


Populations for whom use is Contraindicated

Use is absolutely contraindicated in patients with a known prior sensitization or hypersensitivity to Nitrofural or any other Nitrofuran derivative.

Populations Requiring Restricted or Conditional Use

  • Renal Impairment: Patients with known or suspected kidney impairment are a restricted population. Caution is required, particularly if applying polyethylene glycol (PEG)-containing formulations over large surface areas, due to the risk of excipient absorption.
  • Pregnancy Status: Safe use has not been established during pregnancy, leading to a not recommended status for women of child-bearing potential.
  • Lactation: Breastfeeding women are subject to the restriction to not apply the medicine to the chest area to prevent accidental infant exposure.

Age-Related Eligibility Rules

  • Pediatric and Geriatric Use: Regulatory documents classify use in both children and older adults as not established. This is based on a lack of specific comparative safety and efficacy studies in these age groups, with primary data being derived from adult patients.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Furacilin-LekT (Nitrofural) topical formulations does not contain specific documentation for drug–drug, metabolic, or transporter-based interactions involving the active ingredient. This is consistent with the minimal systemic absorption expected from an antiseptic agent applied externally.

The interaction constraints documented in official labeling primarily concern an excipient present in some product forms and specific patient health conditions.

Official Interaction-Related Constraint

Constraint Area Interacting Substance/Condition Formal Interaction Outcome
Population/Excipient Risk Polyethylene Glycols (PEG) and Impaired Kidney Function Reduced excipient clearance, increasing potential for accumulation and systemic effects.

Formulations of Furacilin-LekT, such as soluble dressings or solutions, may contain the excipient Polyethylene Glycol (PEG). The official regulatory labeling indicates that the PEG component can be absorbed through large or compromised areas of the skin, such as severe burns. In patients with existing impaired kidney function (renal disease), the normal elimination of absorbed Polyethylene Glycols may be compromised. This specific pharmacokinetic interaction raises the chance of excipient-related accumulation and subsequent effects, leading to a constraint on the product’s application in this population and scenario as stated in prescribing information.

Advertisements

Mechanism of Action

Metabolism-Dependent Activation and Cytotoxicity

The mechanism of action for Nitrofural (Nitrofurazone) is triggered by the microbial cell itself. Specific nitroreductase enzymes within the bacteria enzymatically reduce the stable Nitrofural molecule, forming highly reactive intermediates (free radicals). This activation process requires the bacteria's own metabolism, which converts the compound into highly reactive intermediates.

Irreversible Disruption of Essential Cellular Processes

Once activated, these reactive intermediates indiscriminately attack critical bacterial components. They cause irreversible chemical damage to DNA and RNA (blocking replication and transcription) and covalently bind to essential metabolic enzymes (like those in the TCA cycle), resulting in the functional shutdown of the cell's energy and growth pathways. This multi-systemic failure leads to the cessation of cell viability, characterized by a bactericidal effect.

Constraints on Mechanistic Efficacy

The drug's mechanism is constrained by its activation and chemical properties. The mechanism shows reduced activity against organisms lacking the necessary activating enzymes, and its chemically reactive nature means it can be prematurely consumed by binding to non-target organic matter (e.g., tissue debris or pus) within the environment, which reduces the amount of active agent available to interact with bacterial targets.

Advertisements

Dosage and Administration Information

Furacilin-LekT (Nitrofural) is designated strictly for topical administration (external use). The medicine is supplied in high-level forms, including a 0.2% ointment or soluble dressing and tablets intended for the preparation of an aqueous solution, which typically yields a 0.02% concentration. For the ointment, the dosage is defined by the application principle, which mandates covering the affected external area with a sufficient layer of the medication. This coverage can be achieved by applying the ointment directly to the lesion using a spatula or by impregnating sterile gauze to use as a dressing.

The frequency of reapplication is dependent on the chosen wound management technique. The schedule may range from once daily to once weekly, a variability necessary to accommodate different types of dressings and clinical protocols. When preparing the solution from the tablets, the active ingredient is generally dissolved in warm sterile water or isotonic sodium chloride solution to ensure rapid and complete dissolution, with the final solution requiring cooling before use. The procedural steps also specify that flushing the impregnated gauze dressing with sterile saline will facilitate its removal.

Administration is limited to External Use Only. Specific dosage information for pediatric patients is not standardized; therefore, the use and dose of Nitrofural in children must be determined by a qualified healthcare provider. If an application is missed, it should be applied as soon as possible, unless the time for the next scheduled dose is near, in which case the missed application should be skipped.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Furacilin-LekT (Nitrofurazone) is a topical antimicrobial agent that has been the subject of research focused primarily on its use as an adjunctive therapy for preventing and treating bacterial contamination in superficial wounds and burns. Evidence largely evaluates its role in wound management and infection control.


Efficacy in Wound and Burn Management

Clinical trials have investigated the use of topical Nitrofurazone in managing second- and third-degree burns. Studies often examine its effect on reducing microbial contamination in the wound site. Research suggests that it is indicated as an adjunctive treatment, particularly when concerns about bacterial resistance to other common topical agents are present, or during skin grafting procedures where bacterial contamination may affect graft viability.


Infection Prevention

The efficacy of Nitrofurazone-impregnated devices, such as urinary catheters, has been evaluated in randomized controlled trials to determine their potential in reducing catheter-associated urinary tract infections (UTIs). These studies reported a reduction in asymptomatic bacteriuria and funguria, as well as significantly longer times until the onset of these infections, when compared to standard catheters.


Safety Profile and Limitations

Clinical evidence indicates that the most commonly reported adverse event associated with topical Nitrofurazone is allergic contact dermatitis. This reaction is observed in a small percentage of patients. It is noted that, due to the polyethylene glycol (PEG) vehicle in some formulations, caution is exercised in patients with severe kidney function impairment, as PEG absorption through the skin may be limited in elimination. Research concerning the use and effects of this agent in pediatric and geriatric populations is limited.

Key Studies & References

  1. Amniotic Membrane Dressing versus Nitrofurazone-Impregnated Dressing in the Treatment of Second-Degree Burn Wounds: A Randomized Clinical Trial
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Furacilin-LekT (FAQ)


Q: Can children use Furacilin-LekT?

A: Official regulatory documents indicate that use in children is not established, meaning specific safety and efficacy studies for this age group are not standardized. Therefore, the decision regarding use and dosage should be discussed with a qualified healthcare provider.

Q: Is Furacilin-LekT safe to use during pregnancy, according to official documents?

A: According to official product information, the safe use of the medicine during pregnancy has not been established. For this reason, the product is generally listed as not recommended for women who are pregnant or may become pregnant.

Q: What do official sources say about using Furacilin-LekT while breastfeeding?

A: The official regulatory constraints for breastfeeding women state that the product is not recommended for application to the chest area. This is to prevent any accidental exposure of the medicine to the infant.

Q: How long can I use Furacilin-LekT continuously?

A: Official guidance advises against using the product for longer periods than those recommended by a healthcare provider. The maximum duration of continuous use is determined based on the specific condition being treated, as prolonged use can sometimes lead to the risk of superinfection.

Q: Is there a concern about prolonged use of Furacilin-LekT?

A: Yes, regulatory warnings indicate that treatment should be discontinued if signs of sensitization or the overgrowth of non-susceptible organisms (superinfection) occur. This overgrowth is a risk factor associated with antimicrobial use.

Q: How quickly can I expect Furacilin-LekT to start working?

A: Based on patient guidance for this class of antimicrobial agents, users may observe that symptoms related to the infection improve within a few days of starting treatment. The full effect is typically associated with continued application as recommended.

Q: Can Furacilin-LekT be used for a sore throat?

A: Official regulatory documents designate Furacilin-LekT strictly for topical administration, meaning it is intended only for external use on the skin. It is not designed or intended for use in the oral cavity, such as for a sore throat.

Q: Is Furacilin-LekT available over-the-counter?

A: In most regions, official patient information indicates that the medicine is classified as prescription-only (Rx-only). This suggests that a valid prescription from a doctor is typically required to obtain Furacilin-LekT.

Q: What is the most common side effect reported for Furacilin-LekT?

A: The most frequently documented local adverse events reported in regulatory materials fall under Skin and Subcutaneous Tissue Disorders. These reactions primarily include irritation at the application site and the potential development of allergic contact dermatitis (a sensitization reaction).

Q: Is it normal to feel a stinging or burning sensation when using Furacilin-LekT?

A: Official lists of possible adverse reactions frequently document stinging or burning sensations as part of the local skin irritation or sensitization that can occur at the application site. If this sensation is severe, official guidance suggests that discontinuing use may be necessary.

Q: Can I use Furacilin-LekT if I am taking blood pressure medication?

A: The official regulatory profile for topical Furacilin-LekT indicates that there is no specific documentation for drug-drug interactions with systemic medicines. This is consistent with the minimal systemic absorption expected from an antiseptic applied externally.

Q: Is there a list of ingredients in Furacilin-LekT besides the active component?

A: Yes, regulatory documents like the official labeling or product information for each specific product form include a full list of all inactive ingredients (excipients). For example, some product forms may contain Polyethylene Glycols (PEG).

Q: Is Furacilin-LekT approved by the FDA or a similar major regulatory body?

A: The active ingredient, Nitrofural (Nitrofurazone), is recognized by major regulatory bodies. While the active ingredient has historically been approved in many regions, the current approved status and availability of the specific final product formulation may vary by country.

Q: Has Furacilin-LekT been the subject of any recent clinical trials?

A: Studies concerning topical Nitrofurazone have investigated its use as an adjunctive therapy for preventing bacterial contamination in superficial wounds and burns. Research has also examined its role when impregnated into devices like urinary catheters for infection prevention.

Q: What does the research evidence say about the effectiveness of Furacilin-LekT?

A: Official research evidence supports the role of the drug as an adjunctive therapy—meaning it is used alongside other treatments. Studies have focused on its ability to manage and prevent bacterial contamination in superficial wounds and burns.

Q: Is Furacilin-LekT safe to use on open wounds?

A: Regulatory indications for use include application to the affected external area, including lesions, wounds, and burns. This suggests the product is intended for application on damaged skin or tissue as an antiseptic agent.

Q: Can I use Furacilin-LekT with other topical skin products?

A: Official regulatory guidance suggests that users discuss the use of other topical products with a healthcare provider before applying them to the same area of skin simultaneously.

Q: What should I do if I accidentally swallow a small amount of Furacilin-LekT solution?

A: The official safety information emphasizes that the product is strictly for external use and must not be taken by mouth. If accidental ingestion occurs, official safety guidance indicates that immediate contact with a hospital or poison control center may be necessary.

Q: Is there a maximum number of times per day Furacilin-LekT can be used, generally?

A: The official frequency of application is highly dependent on the specific wound management technique being used. According to regulatory documentation, the schedule can vary widely, ranging from application once daily to once weekly.

Q: Can elderly patients use Furacilin-LekT without special considerations?

A: Regulatory documents classify use in older adults as not established, similar to the pediatric population. This is due to a lack of specific comparative safety and efficacy studies for this age group, meaning use requires careful consideration.

Q: What is the risk of resistance developing from using Furacilin-LekT?

A: Regulatory warnings indicate a risk of superinfection, which is the overgrowth of organisms that are not susceptible to the medicine. This is a known possibility with antimicrobial treatments, and official guidance suggests that discontinuing the product may be necessary if superinfection occurs.

Q: Are there different strengths or concentrations of Furacilin-LekT available?

A: Yes, official documents describe different product forms with distinct concentrations. For example, the product may be available as a 0.2% ointment or as tablets for solution preparation that typically yields a 0.02% aqueous concentration.

Q: Does Furacilin-LekT contain alcohol or parabens?

A: Regulatory documents for specific product forms are required to list all inactive ingredients (excipients). To check for the presence of specific ingredients like alcohol or parabens, one would need to refer to the full composition section of the official regulatory labeling for the exact formulation being used.

Q: Is it okay to use expired Furacilin-LekT?

A: Regulatory requirements indicate that any unused or expired medicine should be properly disposed of. The medicine should be handled according to local regulatory requirements for pharmaceutical waste, and the product is not recommended for use past the expiration date.

Q: What kind of studies support the use of Furacilin-LekT?

A: Clinical studies have investigated the use of the active ingredient as an adjunctive therapy for managing bacterial contamination in superficial wounds, burns, and during skin grafting procedures. Research has also supported its use in antimicrobial-impregnated medical devices.

Q: Can I mix Furacilin-LekT with water or saline solution?

A: The official procedure for preparing the solution from the tablets specifies that the active ingredient is generally dissolved in warm sterile water or isotonic sodium chloride solution. This facilitates rapid and complete dissolution for the intended use.

Q: Why is Furacilin-LekT primarily used for external applications?

A: Its mechanism of action is constrained by its chemically reactive nature. Official documents explain that the active agent can be prematurely consumed by binding to non-target organic matter (such as pus or tissue debris), which limits its effectiveness when used systemically or in non-local applications.

Q: Are there any known dietary restrictions when using Furacilin-LekT?

A: Regulatory patient information generally indicates that no specific dietary restrictions are required when an individual is using the topical medication. This is consistent with the minimal systemic absorption expected from an external antiseptic agent.

Advertisements

How should Furacilin-LekT be stored and disposed of?

How to Store and Dispose of Furacilin-LekT (Nitrofural)

Official regulatory documents define specific environmental and security conditions for the storage of Furacilin-LekT to ensure product stability and safety.

Mandatory Storage Conditions

The product must be stored at a temperature not exceeding 25 C (twenty-five degrees Celsius). Furthermore, the official labeling requires the medicine to be stored in a dry place and be protected from light.

Handling and Protection

It is a mandatory requirement that Furacilin-LekT is securely stored out of the sight and reach of children to prevent accidental exposure.

Disposal

If the medicine is unused or has expired, it must be disposed of according to local regulatory requirements for pharmaceutical waste. Specific household disposal instructions are not typically documented in the product's official labeling, necessitating adherence to local guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furacilin-LekT found in:

A-Z Index: